NCT04134923 · RECRUITING
Imaging Biomarkers in Preclinical and Symptomatic AD
This study uses brain scans with a tracer called PIB to look for amyloid, a sticky protein that may be linked to Alzheimer's. It focuses on adult children of parents with and without Alzheimer's, to learn what changes in the brain before symptoms appear. It is an imaging study, not a treatment test, and no phase is listed.
You may qualify if
- Male or female, any race;
- Age ≥ 18 years;
- Active participants currently enrolled in the Knight Alzheimer's Disease Research Center (ADRC) at Washington University.
You're excluded if
- Hypersensitivity to [11C] PIB or any of its excipients;
- Contraindications to PET, CT or MRI (e.g. electronic medical devices, inability to lie still for extended periods) that make it unsafe for the individual to participate;
- Severe claustrophobia;
- Women who are pregnant or breast-feeding will be excluded from PIB PET participation;
- Has any condition that, in the opinion of the Sponsor-Investigator or designee could increase risk to the subject, limit the subject's ability to tolerate the research procedures, or interfere with collection of the data;
- Currently participating in any clinical trial which involves an active study medication or placebo within the past 30 days before scanning and up to 2-weeks past the imaging visit.
- Current or recent (within 12 months prior to screening) participation in research studies involving radioactive agents such that the total research-related radiation dose to the participant in any given year would exceed the limits set forth in the U.S. Code of Federal Regulations (CFR) Title 21 Section 361.1. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?FR=361.1
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-08-07